Compare LND & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LND | IFRX |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | Brazil | Germany |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 373.6M | 303.4M |
| IPO Year | 2010 | 2017 |
| Metric | LND | IFRX |
|---|---|---|
| Price | $3.84 | $2.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 51.9K | ★ 976.3K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.65 | N/A |
| Revenue Next Year | $6.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.46 | $0.80 |
| 52 Week High | $4.45 | $2.95 |
| Indicator | LND | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 63.02 | 60.09 |
| Support Level | $3.70 | $2.25 |
| Resistance Level | $3.88 | $2.57 |
| Average True Range (ATR) | 0.09 | 0.16 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 91.43 | 59.60 |
Brasilagro - Cia Bras de Prop Agricolas is a Brazil-based company, engaged in the acquisition, development, operation, and sale of rural properties suitable for agricultural activities. The business activity of the firm is operated through Real estate, Grains, Sugarcane, Cattle rising, Cotton, and Other segments. The Grains segment is involved in the production and sale of soybean and corn. The Sugarcane segment includes the sale of raw product. The Real Estate segment presents the P&L from operations carried out in the company's subsidiaries. The Cattle Raising segment consists of producing and selling beef calves after weaning, which characterizes the activity as breeding and the Other segment engages in other corporate activities. The majority of revenue is earned from Grain Segment.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.